Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy Chataway

Showing results (91-100 of 182) with videos related to

Pageof 19
Sort By:
Journal of the Neurological Sciences|October 17, 2019
Screening for urinary tract colonisation prior to corticosteroid administration in acute multiple sclerosis relapses: Validation of an updated algorithmFergus O'Herlihy, Nevin A John, Vivien Li, et al.
Trials|August 9, 2022
Optimising recruitment in clinical trials for progressive multiple sclerosis: observational analysis from the MS-SMART and MS-STAT2 randomised controlled trialsThomas Williams, Sarah Alexander, James Blackstone, et al.
Neurology|June 5, 2021
Secondary Progressive Multiple Sclerosis: New InsightsBruce A C Cree, Douglas L Arnold, Jeremy Chataway, et al.
Nature Medicine|September 14, 2023
The role of placebo control in clinical trials for neurodegenerative diseasesArpan R Mehta, James R Carpenter, Jennifer M Nicholas, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 16, 2015
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribineJulia Pakpoor, Giulio Disanto, Daniel R Altmann, et al.
European Journal of Neurology|April 17, 2026
Erythrocyte Fragility in Progressive Multiple SclerosisCarmen Jacob, Thomas E Williams, Charlotte M Stuart, et al.
Multiple Sclerosis and Related Disorders|November 27, 2018
Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesisIeva Eskyte, Ana Manzano, George Pepper, et al.
The Lancet. Neurology|July 13, 2010
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trialRaju Kapoor, Julian Furby, Thomas Hayton, et al.
The Lancet. Neurology|May 30, 2020
MS-SMART study: systematic sampling bias concerns - Authors' replyJeremy Chataway, Floriana De Angelis, Peter Connick, et al.
Practical Neurology|May 22, 2020
How to diagnose difficult white matter disordersThomas Williams, Henry Houlden, Elaine Murphy, et al.
Pageof 19

Showing results (91-100 of 182) with videos related to

Sort By:
Pageof 19
Journal of the Neurological Sciences|October 17, 2019
Screening for urinary tract colonisation prior to corticosteroid administration in acute multiple sclerosis relapses: Validation of an updated algorithmFergus O'Herlihy, Nevin A John, Vivien Li, et al.
Trials|August 9, 2022
Optimising recruitment in clinical trials for progressive multiple sclerosis: observational analysis from the MS-SMART and MS-STAT2 randomised controlled trialsThomas Williams, Sarah Alexander, James Blackstone, et al.
Neurology|June 5, 2021
Secondary Progressive Multiple Sclerosis: New InsightsBruce A C Cree, Douglas L Arnold, Jeremy Chataway, et al.
Nature Medicine|September 14, 2023
The role of placebo control in clinical trials for neurodegenerative diseasesArpan R Mehta, James R Carpenter, Jennifer M Nicholas, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 16, 2015
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribineJulia Pakpoor, Giulio Disanto, Daniel R Altmann, et al.
European Journal of Neurology|April 17, 2026
Erythrocyte Fragility in Progressive Multiple SclerosisCarmen Jacob, Thomas E Williams, Charlotte M Stuart, et al.
Multiple Sclerosis and Related Disorders|November 27, 2018
Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesisIeva Eskyte, Ana Manzano, George Pepper, et al.
The Lancet. Neurology|July 13, 2010
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trialRaju Kapoor, Julian Furby, Thomas Hayton, et al.
The Lancet. Neurology|May 30, 2020
MS-SMART study: systematic sampling bias concerns - Authors' replyJeremy Chataway, Floriana De Angelis, Peter Connick, et al.
Practical Neurology|May 22, 2020
How to diagnose difficult white matter disordersThomas Williams, Henry Houlden, Elaine Murphy, et al.
Pageof 19